Inovio Pharmaceuticals Presents at Citizens Life Sciences Conference 2026

Inovio Pharmaceuticals has submitted its BLA for INO-3107, a potential treatment for recurrent respiratory papillomatosis caused by HPV types 6 and 11, under the accelerated approval program. The company has requested a meeting with FDA to discuss preliminary comments received in the file acceptance letter and is not currently planning to seek approval under the traditional pathway. The PDUFA target date is October 30 this year.